Cancer Chemotherapy and Pharmacology

, Volume 70, Issue 5, pp 735–741 | Cite as

Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy

  • Byung Woog Kang
  • Ji Yun Jeong
  • Yee Soo Chae
  • Soo Jung Lee
  • Yoo Jin Lee
  • Jun Young Choi
  • In-Kyu Lee
  • Seong Woo Jeon
  • Han Ik Bae
  • Da Keun Lee
  • Oh-kyoung Kwon
  • Ho Young Chung
  • Wansik Yu
  • Jong Gwang Kim
Original Article

Abstract

Purpose

The present study analyzed the expression of phosphorylated AMP-activated protein kinase (pAMPK), Fyn kinase, and pyruvate dehydrogenase kinase-1 (PDK-1) and their impact on the survival of patients with resected gastric cancer who received cisplatin-based adjuvant chemotherapy.

Patients and methods

Korean patients with stage II–IV (M0) gastric adenocarcinoma who underwent a gastrectomy with D2 lymph node resection and received a combination regimen of cisplatin and S-1 were enrolled. Immunohistochemistry was carried out to determine the expression of pAMPK, Fyn kinase, and PDK-1 in operative specimens of gastric cancer. The expression was divided into two groups according to the intensity score (negative: 0 or 1+ and positive: 2+ or 3+).

Results

From January 2006 to July 2010, 73 tumor samples obtained from 74 patients were analyzed. Forty patients were included in the pAMPK-positive group, while 33 patients were included in the pAMPK-negative group. Meanwhile, positive Fyn kinase expression was observed in only 10 patients (13.7 %), and there was no or very weak PDK-1 staining. The clinicopathologic characteristics were similar between the two groups according to the expression of pAMPK. With a median follow-up duration of 26.5 months (2.6–73.2), the estimated 3-year relapse-free survival (RFS) and overall survival rates were 55.0 and 78.4 %, respectively. In a multivariate analysis adjusted for age, sex, Lauren classification, and stage, the pAMPK-negative group was significantly associated with improved RFS (Hazard ratio = 0.459, 95 % CI 0.109–0.711, P = 0.043).

Conclusion

A low expression of pAMPK was found to be correlated with better RFS in patients with resected gastric cancer treated with adjuvant cisplatin-based chemotherapy.

Keywords

AMP-activated protein kinase Gastric cancer Cisplatin Adjuvant chemotherapy Prognosis 

References

  1. 1.
    Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17):1729–1737PubMedCrossRefGoogle Scholar
  2. 2.
    Lim L, Michael M, Mann GB, Leong T (2005) Adjuvant therapy in gastric cancer. J Clin Oncol 23(25):6220–6232PubMedCrossRefGoogle Scholar
  3. 3.
    Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29(33):4387–4393PubMedCrossRefGoogle Scholar
  4. 4.
    Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT (2009) Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 45(16):2867–2873PubMedCrossRefGoogle Scholar
  5. 5.
    Chen J (2011) Multiple signal pathways in obesity-associated cancer. Obes Rev 12(12):1063–1070PubMedCrossRefGoogle Scholar
  6. 6.
    Faulds MH, Dahlman-Wright K (2012) Metabolic diseases and cancer risk. Curr Opin Oncol 24(1):58–61PubMedCrossRefGoogle Scholar
  7. 7.
    Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M (2011) Emerging metabolic targets in cancer therapy. Front Biosci 16:1844–1860PubMedCrossRefGoogle Scholar
  8. 8.
    Hardie DG (2011) AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans 39(1):1–13PubMedCrossRefGoogle Scholar
  9. 9.
    Yun H, Ha J (2011) AMP-activated protein kinase modulators: a patent review (2006–2010). Expert Opin Ther Pat 21(7):983–1005PubMedCrossRefGoogle Scholar
  10. 10.
    Wang W, Guan KL (2009) AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 196(1):55–63CrossRefGoogle Scholar
  11. 11.
    Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C (2011) Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 25(4):1005–1012PubMedGoogle Scholar
  12. 12.
    Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM (2009) Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9:307PubMedCrossRefGoogle Scholar
  13. 13.
    Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8(4):733–741PubMedCrossRefGoogle Scholar
  14. 14.
    Yu SY, Chan DW, Liu VW, Ngan HY (2009) Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol 30(2):80–85PubMedCrossRefGoogle Scholar
  15. 15.
    William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY (2012) The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 23(1):78–85PubMedCrossRefGoogle Scholar
  16. 16.
    Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V (2009) AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 13(9B):3644–3654PubMedCrossRefGoogle Scholar
  17. 17.
    Kim HS, Hwang JT, Yun H, Chi SG, Lee SJ, Kang I, Yoon KS, Choe WJ, Kim SS, Ha J (2008) Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283(7):3731–3742PubMedCrossRefGoogle Scholar
  18. 18.
    Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Seo J, Lee YH, Kwon O, Chung HY, Yu W (2012) Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs 30(4):1671–1675PubMedCrossRefGoogle Scholar
  19. 19.
    Carling D, Zammit VA, Hardie DG (1987) A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 223(2):217–222PubMedCrossRefGoogle Scholar
  20. 20.
    Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25(18):1895–1908PubMedCrossRefGoogle Scholar
  21. 21.
    Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S, Nishizaki T (2004) Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem Pharmacol 67(10):2005–2011PubMedCrossRefGoogle Scholar
  22. 22.
    Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279PubMedCrossRefGoogle Scholar
  23. 23.
    Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S (2010) Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 103(7):1025–1033PubMedCrossRefGoogle Scholar
  24. 24.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Byung Woog Kang
    • 1
  • Ji Yun Jeong
    • 2
  • Yee Soo Chae
    • 1
  • Soo Jung Lee
    • 1
  • Yoo Jin Lee
    • 1
  • Jun Young Choi
    • 1
  • In-Kyu Lee
    • 2
  • Seong Woo Jeon
    • 3
  • Han Ik Bae
    • 4
  • Da Keun Lee
    • 4
  • Oh-kyoung Kwon
    • 5
  • Ho Young Chung
    • 5
  • Wansik Yu
    • 5
  • Jong Gwang Kim
    • 1
  1. 1.Department of Hematology/Oncology, Kyungpook National University HospitalKyungpook National University School of MedicineDaeguSouth Korea
  2. 2.Department of Endocrinology, Kyungpook National University HospitalKyungpook National University School of MedicineDaeguSouth Korea
  3. 3.Department of Gastroenterology, Kyungpook National University HospitalKyungpook National University School of MedicineDaeguSouth Korea
  4. 4.Department of Pathology, Kyungpook National University HospitalKyungpook National University School of MedicineDaeguSouth Korea
  5. 5.Department of Surgery, Kyungpook National University HospitalKyungpook National University School of MedicineDaeguSouth Korea

Personalised recommendations